Twenty-three patients with malignant lymphoma, (7 Hodgkin's, and 16 non-Hodgkin's) in different phases of disease were autografted in 4 Italian Haematology institutions using only chemotherapy-mobilized blood stem cells (BSC) collected by apheresis. Clinical and laboratory data were analysed centrally and showed mean collection yields of 8.1 x 10(8) kg mononuclear cells (MNC) (SE 0.5; range 2.6-13.8) and 24.1 x 10(4) kg CFU-GM (SE 7.4; range 1.4-162.9). The mean times required to attain 0.5 x 10(9)/l neutrophils and 50 x 10(9)/l platelets after marrow-ablative high-dose chemo+radiotherapy and BSC reinfusion were 14.9 days (SE 1.5; range 7-38) and 18.6 days (SE 2.6; range 6-49) respectively. The incidence of early deaths was < 5\% and the requirement for support with blood product transfusion was moderate. The progression free survival (PFS) is > 50\% at 3 years with a median follow-up of 17.3 months. Results were significantly better for patients autografted in remission. These results suggest that autologous blood stem cell transplantation (ABSCT) may be proposed for the primary treatment of poor prognosis malignant lymphomas. However, ABSCT needs to be compared with autologous bone marrow transplantation (ABMT) followed by infusion of growth factors to accelerate recovery.

Autologous blood stem cell transplantation in malignant lymphomas: an Italian Cooperative Study / I., Majolino; A. M., Quaglietta; A., Iacone; R., Scime; G., Fioritoni; L. D., Rosa; Pierelli, Luca; A., Indovina; A., Spadano; A. D., Laurenzi. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 7 Suppl:(1992), pp. 11-16. [10.3109/10428199209061557]

Autologous blood stem cell transplantation in malignant lymphomas: an Italian Cooperative Study.

PIERELLI, LUCA;
1992

Abstract

Twenty-three patients with malignant lymphoma, (7 Hodgkin's, and 16 non-Hodgkin's) in different phases of disease were autografted in 4 Italian Haematology institutions using only chemotherapy-mobilized blood stem cells (BSC) collected by apheresis. Clinical and laboratory data were analysed centrally and showed mean collection yields of 8.1 x 10(8) kg mononuclear cells (MNC) (SE 0.5; range 2.6-13.8) and 24.1 x 10(4) kg CFU-GM (SE 7.4; range 1.4-162.9). The mean times required to attain 0.5 x 10(9)/l neutrophils and 50 x 10(9)/l platelets after marrow-ablative high-dose chemo+radiotherapy and BSC reinfusion were 14.9 days (SE 1.5; range 7-38) and 18.6 days (SE 2.6; range 6-49) respectively. The incidence of early deaths was < 5\% and the requirement for support with blood product transfusion was moderate. The progression free survival (PFS) is > 50\% at 3 years with a median follow-up of 17.3 months. Results were significantly better for patients autografted in remission. These results suggest that autologous blood stem cell transplantation (ABSCT) may be proposed for the primary treatment of poor prognosis malignant lymphomas. However, ABSCT needs to be compared with autologous bone marrow transplantation (ABMT) followed by infusion of growth factors to accelerate recovery.
1992
Adolescent; Adult; Cell Separation; methods; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; mortality/therapy; Male; Middle Aged; Survival Rate; Transplantation; Autologous
01 Pubblicazione su rivista::01a Articolo in rivista
Autologous blood stem cell transplantation in malignant lymphomas: an Italian Cooperative Study / I., Majolino; A. M., Quaglietta; A., Iacone; R., Scime; G., Fioritoni; L. D., Rosa; Pierelli, Luca; A., Indovina; A., Spadano; A. D., Laurenzi. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 7 Suppl:(1992), pp. 11-16. [10.3109/10428199209061557]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/399329
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact